BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17478016)

  • 21. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.
    Bhaumik S; Basu R; Sen S; Naskar K; Roy S
    Vaccine; 2009 Feb; 27(9):1306-16. PubMed ID: 19162111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells.
    Carrión J; Folgueira C; Alonso C
    Vaccine; 2008 May; 26(20):2537-44. PubMed ID: 18400342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice.
    Rolão N; Cortes S; Gomes-Pereira S; Campino L
    Exp Parasitol; 2007 Mar; 115(3):270-6. PubMed ID: 17087930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N; Jaffe CL
    J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
    Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V
    Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with a CD4
    Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
    Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis.
    de Lima VM; Ikeda FA; Rossi CN; Feitosa MM; Vasconcelos RO; Nunes CM; Goto H
    Vet Immunol Immunopathol; 2010 Jun; 135(3-4):296-302. PubMed ID: 20132994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
    Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
    Ribeiro PAF; Vale DL; Dias DS; Lage DP; Mendonça DVC; Ramos FF; Carvalho LM; Carvalho AMRS; Steiner BT; Roque MC; Oliveira-da-Silva JA; Oliveira JS; Tavares GSV; Galvani NC; Martins VT; Chávez-Fumagalli MA; Roatt BM; Moreira RLF; Menezes-Souza D; Oliveira MC; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
    Cytokine; 2020 May; 129():155031. PubMed ID: 32062145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
    Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
    Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.
    Resende DM; Caetano BC; Dutra MS; Penido ML; Abrantes CF; Verly RM; Resende JM; Piló-Veloso D; Rezende SA; Bruna-Romero O; Fernandes AP; Gazzinelli RT
    Vaccine; 2008 Aug; 26(35):4585-93. PubMed ID: 18588933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic cellular immune responses in mice with "cure" and "non-cure" phenotype to Leishmania infantum infection: importance of CD8+ T cells and TGF-beta production.
    Gomes-Pereira S; Rodrigues OR; Rolão N; Almeida PD; Santos-Gomes GM
    FEMS Immunol Med Microbiol; 2004 May; 41(1):59-68. PubMed ID: 15094168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition.
    Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Colloids Surf B Biointerfaces; 2009 Nov; 74(1):37-44. PubMed ID: 19615870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis.
    Carrillo E; Crusat M; Nieto J; Chicharro C; Thomas Mdel C; Martínez E; Valladares B; Cañavate C; Requena JM; López MC; Alvar J; Moreno J
    Vaccine; 2008 Mar; 26(15):1902-11. PubMed ID: 18321614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis.
    Agallou M; Smirlis D; Soteriadou KP; Karagouni E
    Vaccine; 2012 Jul; 30(34):5086-93. PubMed ID: 22704924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
    Rafati S; Zahedifard F; Nazgouee F
    Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis.
    Paul J; Karmakar S; De T
    Eur J Immunol; 2012 Aug; 42(8):2087-99. PubMed ID: 22622993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.